The reading behind the posts

These are the sources linked in the posts. Each description says what I used it for. A link can help you check a sentence; it doesn’t make a small study bigger.

A medicine’s label describes approved uses and warnings. A trial tests a particular question. A review looks across studies. FDA’s compounding pages explain a different set of questions about ingredients and safety. I read each for the job it can actually do.

Sources in the posts

• FDA explains made-to-order medicines

  Compounded medicines do not carry FDA approval, even when they meet the law.

• FDA records peptide safety concerns

  Withdrawn requests and Category 2 are separate tables. Neither is a safety clearance.

• FDA sets out the ingredient tests

  Ingredient conditions are one part of the rules for compounding for a named patient.

• Semaglutide prescribing information

  Weight-management uses, stomach side effects and serious warnings, including the thyroid warning.

• Semaglutide in an adult weight trial

  Adults without diabetes lost more weight with semaglutide than placebo, alongside lifestyle support.

• Tirzepatide prescribing information

  Weight-management uses and warnings for tirzepatide. It acts on two gut-hormone targets.

• Continuing or withdrawing tirzepatide

  Participants who switched to placebo regained weight; those continuing tirzepatide lost more.

• Copper peptide in skin-cell cultures

  More collagen in cells in a dish, rather than a test of face cream.

• Copper-peptide care after laser treatment

  After laser treatment, the small trial found no clear group difference in redness or wrinkles, but satisfaction was higher with copper-peptide care.

• Copper peptide after rat ligament surgery

  Knee looseness briefly improved in rats; the study could not show a clear difference in walking or the repaired ligament’s breaking strength.

• FDA explains the cosmetic boundary

  Intended uses help determine whether a product is a cosmetic or a drug.

• An oral NAD+ precursor trial

  Nicotinamide riboside raised blood NAD+. That measurement does not establish an everyday energy benefit.

• Human evidence for NAD+ precursors

  Human precursor studies show limited evidence of health benefits, despite promising biology.

• FDA’s determination on old sermorelin products

  FDA found the old products had not left sale for safety or effectiveness reasons.

• A small study in older men

  Growth hormone rose; measured muscle and fat didn’t change. Some performance tests improved.

• A review of childhood sermorelin use

  Older, mainly childhood evidence includes flushing and injection-site pain. Adult safety remains uncertain.

• A small selank anxiety comparison

  Compared selank with another medicine. The abstract describes no group without active treatment.

• Kisspeptin and low sexual desire

  Short exposure to kisspeptin-54 changed sexual-response measures. It did not test lasting treatment.

• Kisspeptin’s investigational clinical status

  A review of human research on kisspeptin, which still has no approved product.